OSBP

Oxysterol-binding protein 1 · P22059 · OSBP on Sugi Atlas →

25,241 patent compounds predicted against OSBP, 22,644 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Schweinfurthin B (SCHEMBL847454)	0.85	14/20
Schweinfurthin A (SCHEMBL847068)	1.00	11/20
Cholesterol (SCHEMBL2156)	1.00	6/20
Cholesterol (SCHEMBL2157)	1.00	6/20
Cholesterol (SCHEMBL157673)	1.00	6/20
SCHEMBL159618	1.00	6/20
SCHEMBL177267	1.00	6/20
SCHEMBL177268	1.00	6/20
Cholesterol (SCHEMBL255311)	1.00	6/20
SCHEMBL288494	1.00	6/20
SCHEMBL288733	1.00	6/20
Cholesterol (SCHEMBL413494)	1.00	6/20
Cholesterol (SCHEMBL247958)	0.98	6/20
Cholesterol (SCHEMBL335591)	0.98	6/20
Cholesterol (SCHEMBL653608)	0.98	6/20
Cholesterol (SCHEMBL653609)	0.98	6/20
Cholesterol (SCHEMBL720337)	0.98	6/20
Cholesterol (SCHEMBL720339)	0.98	6/20
Cholesterol (SCHEMBL454868)	0.94	6/20
Cholesterol (SCHEMBL454869)	0.94	6/20

Clinical trials — most relevant to OSBP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis	PHASE2	ACTIVE_NOT_RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)	PHASE2	COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes	nan	COMPLETED
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors	nan	NOT_YET_RECRUITING
Epidemiology of Atherosclerosis	nan	COMPLETED
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)	nan	COMPLETED
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study	nan	COMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
Prospective Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) Risk	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
The Role of Sugars in Fat Accumulation in the Liver	nan	RECRUITING
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health	nan	UNKNOWN
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study)	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED
LXR and Oocyte Meiosis Resumption	nan	UNKNOWN
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy	nan	NOT_YET_RECRUITING
Mild Intermittent Hypoxia and Its Multipronged Effect on Sleep Apnea	nan	RECRUITING
Statin Therapy and COVID-19 Infection	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients	nan	UNKNOWN
Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults	nan	COMPLETED
FGF19 in Obstructive Cholestasis: Unveil the Signal	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a OSBP binder may also engage these)

Protein	Name	Similarity
Q3B7Z2	—	1.000	Q3B7Z2 →
P16258	—	1.000	P16258 →
A2A8Z1	—	0.995	A2A8Z1 →
Q96SU4	—	0.992	Q96SU4 →
Q0IJ05	—	0.992	Q0IJ05 →
Q5R9W4	—	0.992	Q5R9W4 →
Q8CI95	—	0.990	Q8CI95 →
Q9BZF3	—	0.990	Q9BZF3 →
Q9BXB4	—	0.989	Q9BXB4 →
O80866	—	0.989	O80866 →
Q8BXR9	—	0.988	Q8BXR9 →
OSBPL3	Oxysterol-binding protein-related protein 3	0.987	landscape →
Q8K4M9	—	0.987	Q8K4M9 →
Q91XL9	—	0.985	Q91XL9 →
Q9SU36	—	0.984	Q9SU36 →
OSBP2	Oxysterol-binding protein 2	0.984	landscape →
Q8L751	—	0.984	Q8L751 →
Q5QNQ6	—	0.983	Q5QNQ6 →
Q9DBS9	—	0.983	Q9DBS9 →
Q9BXW6	—	0.983	Q9BXW6 →
E9PUQ8	—	0.982	E9PUQ8 →
Q9SAF0	—	0.982	Q9SAF0 →
Q93Y40	—	0.982	Q93Y40 →
Q92503	—	0.982	Q92503 →
Q940Y1	—	0.981	Q940Y1 →
Q86XP1	—	0.980	Q86XP1 →
Q16760	—	0.979	Q16760 →
Q64398	—	0.979	Q64398 →
S4R1M9	—	0.979	S4R1M9 →
ARFGEF1	Brefeldin A-inhibited guanine nucleotide-exchange protein 1	0.979	landscape →